New drug combo for advanced cancers tested in early trial
NCT ID NCT03522142
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 22 times
Summary
This early-phase study tested an experimental drug called INCB081776, alone or combined with the immunotherapy retifanlimab, in 83 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see early signs of activity. The study was terminated early, so full results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Erasmus Medical Center
Rotterdam, 3015 GD, Netherlands
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Haukeland University Hospital
Bergen, 05021, Norway
-
Karolinska University Hospital Solna
Stockholm, 171 76, Sweden
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, 1066 CX, Netherlands
-
Odense University Hospital
Odense C, 05000, Denmark
-
Rigshospitalet Uni of Hospital of Copenhagen
Copenhagen, 02100, Denmark
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Skane University Hospital Lund
Lund, 22185, Sweden
-
University Medical Center Groningen
Groningen, 9713GZ, Netherlands
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15232, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
Utprøvingsenheten, Oslo University Hospital Radiumhospitalet
Oslo, 00379, Norway
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB081776 (an experimental drug) and retifanlimab (an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The study was terminated early, so results may be limited and may not lead to a viable treatment.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.